Ligand Pharms General CVR (LGNYZ) Revenue by Year
Ligand Pharms General CVR generated $268.1M in revenue in fiscal year 2025. This represents an increase of 60.4% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $253.8M in revenue. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Ligand Pharms General CVR has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LGNYZ Revenue by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $253.8M | $268.1M+60.4% | $167.1M+27.3% | $131.3M-33.1% | $196.2M-18.8% | $241.5M+47.7% | $163.6M+36.0% | $120.3M-52.2% | $251.5M+78.2% | $141.1M+29.5% | $109.0M+51.5% | $71.9M+11.4% | $64.5M+31.8% | $49.0M+56.0% | $31.4M+4.5% | $30.0M |
TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
LGNYZ Revenue by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What revenue means
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.
More Ligand Pharms General CVR financials
Frequently Asked Questions
Ligand Pharms General CVR generated $268.1M in revenue in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) revenue rose by 60.4% year over year, from $167.1M to $268.1M in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported $253.8M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Ligand Pharms General CVR (LGNYZ) revenue went from $30.0M in fiscal year 2011 to $268.1M in fiscal year 2025.
Ligand Pharms General CVR (LGNYZ) reported $78.7M in revenue in Q3 2026. This represents a decrease of 31.8% from the same quarter a year earlier.
Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Ligand Pharms General CVR (LGNYZ) reported on that line in every period on record.